OBN spotlights Milton Park innovators

We were proud to see three Milton Park occupiers as finalists at the prestigious OBN Awards 2025

Hosted by OBN, a not-for-profit membership organisation which supports life science start-ups, the awards recognise innovation across the UK’s life sciences sector and celebrate companies of all sizes making ground-breaking contributions.

On the night, we were delighted to see Arctoris announced as the winner of the Most Impactful CRO of the Year category.

The award category champions Contract Research Organisations (CRO) which provide support to the pharmaceutical, biotechnology and medical device industries in the form of outsourced research services.

The Arctoris team, based at Milton Park, provide automated drug discovery services, which combine robotics, data and AI to help partners accelerate research programmes.

The team’s award highlighted the distinctiveness and power of its drug discovery platform and the data quality behind the approach.

The category also emphasised Arctoris’ ability to execute complex research programmes reliably, at speed and scale, alongside its cross-disciplinary collaboration, which is driving ambitious outcomes for its partners.

Although they didn’t take home the top spot, we were also delighted to see Greywolf Therapeutics and Replimune announced as finalists for the Best Established Biotech Company Award, a category which Adaptimmune won last year.

Replimune’s team focus on developing oncolytic immunotherapies designed to improve outcomes for people with cancer, whilst Greywolf Therapeutics is advancing antigen modulation technology that modulates the immune system by controlling T-cell responses.

Milton Park was also proud to sponsor the OBN Award for Best Start-up Biotech Company on the night, which was awarded to Draig Therapeutics. We would also like to congratulate congratulate BlackfinBio and ClotProtect Therapeutics as finalists in this year’s category.